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Objective: To study the clinical profile, diagnostic methods and management in patients
with symptomatic pulmonary embolism (PE).
Methods: Retrospective assessment of clinical features and management of patients pre-
senting with symptomatic pulmonary embolism from January 2005 to March 2012.
Results: 35 patients who were newly diagnosed to have pulmonary embolism with a mean
age of 52.1 years were included in the study. Dyspnea (91.4%) and syncope (22.8%) were the
predominant symptoms. Echocardiography was done in all patients. 30 patients (85.7%)
had pulmonary arterial hypertension, 31 patients (88.5%) had evidence of RV dysfunction
and 4 patients (16.7%) had evidence of thrombus in PA, RV. Out of 35 patients, 34 patients
(97.14%) showed positive D-dimer reports. Among 35 patients, 24 (68.5%) had positive
troponin values. V/Q scan was done in 14 patients (40%) and CT pulmonary angiogram
(CTPA) was done in 24 patients (68.5%.). Thrombolysis was done is 24 patients (68.5%). All
patients received lowmolecular weight heparin followed by warfarin. Of the 35 patients, 34
(97.1%) were discharged and were under regular follow up for 6 months and one patient
died during the hospital stay.
Conclusion: Pulmonary embolism is a common problem and can be easily diagnosed pro-
vided it is clinically suspected. Early diagnosis and aggressive management is the key to
successful outcome.
Copyright ª 2014, Cardiological Society of India. All rights reserved.3; fax: þ91 44 26565859.
.in, drcals2005@yahoo.co.in (A.S. Mullasari).
2014, Cardiological Society of India. All rights reserved.
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Pulmonary embolism is a common and potentially lethal
condition. Most patients who succumb to pulmonary embo-
lism do so within the first few hours of the event. Ten percent
of PE is fatal in the first hour.1 Mortality rate of diagnosed and
treated pulmonary embolism ranges from 3 to 8%, but in-
creases to about 30% in untreated pulmonary embolism.1
Most of the deaths occur when the diagnosis is delayed or
never made. Despite diagnostic advances, delays in pulmo-
nary embolism diagnosis are common and represent an
important issue.2
A pulmonary embolism is also characterized as central or
peripheral, depending on the location or the arterial branch
involved. Central vascular zones include the main pulmonary
artery, the left and rightmain pulmonary arteries, the anterior
trunk, the right and left interlobar arteries, and lobar arteries.
A pulmonary embolus is characterized as massive when it
involves main pulmonary arteries or when it results in he-
modynamic compromise. Peripheral vascular zones include
the segmental and subsegmental arteries.
The most important conceptual advance regarding pulmo-
nary embolism over the last several decades has been the real-
ization that pulmonary embolism is not a disease; rather,
pulmonary embolism is a complication of venous thromboem-
bolism. Pulmonary embolism is present in 60e80% of patients
withDVTandmore thanhalf thesepatientsare asymptomatic.3
Clinical signs and symptoms for pulmonary embolism are
nonspecific; therefore, patients suspected of having pulmo-
nary embolism because of unexplained dyspnea, tachypnea,
or chest pain or the presence of risk factors for pulmonary
embolismmust undergo diagnostic tests until the diagnosis is
ascertained or eliminated or an alternative diagnosis is
confirmed. Further, routine laboratory findings are nonspe-
cific and are not helpful in pulmonary embolism, although
theymay suggest another diagnosis. However with the advent
of spiral CT pulmonary angiogram (CTPA), there is now an
increased recognition of this entity in India. In spite of rapid
advances in the diagnosis and management of PE, it is still
unreported from India. Most of the reports are limited to au-
topsy reports and short case series.4 In this study, we describe
our experience with the diagnosis and management of pa-
tients with symptomatic PE.Table 1 e Predisposing factors in patients with
pulmonary embolism.
Predisposing factors No of patients n-35
Immobilization history 8 (22.8%)
Malignancy 2 (5.7%)
Protein C, protein S deficiency 1 (2.8%)
HIV disease 1 (2.8%)2. Materials and methods
A retrospective study of patients admitted with acute pul-
monary thromboembolism at our institute from January 2005
to March 2012 were selected. All patients diagnosed as acute
pulmonary embolism who had no pre-existing cardiac or
pulmonary disease with no previous history of pulmonary
embolism were included in the study. Their clinical presen-
tation, investigation and management were analyzed. A pa-
tient was diagnosed to have pulmonary embolism if there is
evidence of thrombus in CT pulmonary angiogram or a high
probability ventilation perfusion scan.
Patients with pulmonary embolism were classified as
massive if there was evidence of hemodynamic compromise(defined as systolic BP <90 mmHg) and as submassive if there
was right ventricular dysfunction on echocardiography with
no hemodynamic compromise. Patients without any evidence
of these features were labeled as minor pulmonary embolism
cases.
D-dimer testing was done using enzyme linked fluorescent
assay. The normal value is 0e500 ng/ml. Any value greater
than 500 ng/ml is considered positive. Troponin I was done
using electrochemiluminescence method and a value greater
than 0.03 was considered abnormal. Echocardiogram was
done using Philips IE5 machine. Pulmonary arterial pressure
was calculated by TR jet velocity using Bernoulli’s method
(p ¼ 4v2) and RV function was assessed by eyeball method and
also by Tricuspid Annular Plane Systolic Excursion (TAPSE).
TAPSE less than 16 mm indicates RV systolic dysfunction.
Pulmonary hypertension was categorized as mild, moderate,
or severe based on pulmonary artery systolic pressures (mild:
40e45 mmHg, moderate: 46e60 mmHg, or severe >60 mmHg).
Ventilation perfusion scan was done using intravenous in-
jection of radioactive technetium macro aggregated albumin
(Tc 99m MAA). CT pulmonary angiogram was done using 64
slice CT scanner (SOMATOM sensation 64). Apart from routine
blood counts, hematological profile, all patients had a protein
C, S values, antithrombin III, antiphospholipid antibody and
homocysteine levels. Patients who were eligible for throm-
bolytic therapy were lysed using streptokinase bolus of 2.5
lakh units followed by an infusion of 1 lakh units per hour for a
period of 24e48 h. Rest of the patients were anticoagulated
with low molecular weight heparin. The patients were clini-
cally followed up for a period of 6 months.3. Results
35 patients who were newly diagnosed to have acute pulmo-
nary embolism were included in the study. Their mean age
was 52.1 years. Among 35 patients, 22 (62.8%) were males and
13 (37.2%) were females (Table 2).
Out of 35 patients, 8 patients had a history of immobiliza-
tion for a minimum of 2 weeks, 2 patients had carcinoma, one
patient had confirmed HIV disease and one patient had pro-
tein C, protein S deficiency (Table 1).
The most common clinical presentation is dyspnea (91.4%)
followed by syncope (22.8%). The other symptoms being chest
pain (17.1%), fever (11.4%) and cough (11.4%) (Table 2). The
mean duration of symptom onset to hospitalization was 6.2
days.
The most common finding in ECG is sinus tachycardia
(91.4%) followed by RV strain pattern (65.7%), S1Q3T3 pattern
(34.2%) and RBBB (20%) (Table 2).
Table 2 e Clinical features and diagnostic methods In
patients with PE.
Clinical features and diagnostic
methods
No
N-35
Dyspnea 32 (91.4%)
Syncope 8 (22.8%)
Chest pain 6 (17.1%)
Fever 4 (11.4%)
Cough 4 (11.4%)
ECG abnormalities
- Sinus tachycardia 32 (91.4%)
- RV strain pattern 23 (65.7%)
- S1Q3T3 pattern 19 (34.2%)
- RBBB 7 (20%)
Chest X-ray abnormalities
- Normal chest X-ray 30 (85.7%)
- Wedge shaped opacity 2 (5.7%)
- Lobar collapse 2 (5.7%)
- Pleural effusion 1 (2.8%)
Echocardiography
- Pulmonary arterial hypertension 30 (85.7%)
- RV dysfunction 31 (88.5%)
- Thrombus in pulmonary arteries,
RV
4 (16.7%)
V/Q scan 14 (40%)
- Perfusion defects present 11 (78.5%)
- No perfusion defects 3 (21.5%)
CT pulmonary angiogram 24 (68.5%)
- Thrombus in main and lobar
arteries
20 (83.3%)
- Thrombus in subsegmental
arteries
4 (16.7%)
Venous Doppler lower limbs
Evidence of DVT 28 (80%)
D-Dimer Positive 34 (97.1%)
Toponin I Positive 24 (68.5%)
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remaining five patients, two had wedge shaped opacity sug-
gestive of pulmonary infarct, 2 had lung collapse and one had
pleural effusion.
Out of 35 patients, 34 patients (97.14%) showed positive D-
dimer reports. Among 35 patients, 24 (68.5%) had positive
troponin values. Venous Doppler of lower limbs was done in
all patients. 28 patients (80%) had evidence of DVT in lower
limbs (Table 2).
Echocardiography was done in all patients. 31 patients
(88.5%) had evidence of RV dysfunction and 30 patients (85.7%)
had pulmonary arterial hypertension, 22 patients had severe
PAH and 8 patients had moderate PAH at presentation.
Thrombus was visualized in pulmonary arteries in 3 patients
and right ventricle in one patient (Table 2).
Ventilation Perfusion (V/Q) scan was done in 14 patients
(40%) and CT pulmonary angiogram was done in 24 patients
(68.5%). Out of 14 patients who underwent V/Q scan showed
perfusion defects (Fig. 1) suggestive of pulmonary embolism in
11 patients. Among 24 patients who underwent CTPA, 20 pa-
tients had thrombus located in the main, and lobar arteries
(Fig. 2). The remaining 4 patients (16.7%) had thrombus seen in
subsegmental vessels.
Massive pulmonary embolism was diagnosed in 10 pa-
tients (28.5%), submassive pulmonary embolism in 21 patients
(60%) and rest of 4 patients (11.5%) had minor pulmonaryembolism. Out of 31 patients in whom thrombolysis was
indicated, 24 patients (77.4%) were thrombolyzed. In the
remaining 7 patients, thrombolysis was deferred in 4 patients
due to absolute contraindication for thrombolysis and 3 pa-
tients had delayed presentation (>3 weeks) from symptom
onset. All patients were thrombolyzed with streptokinase.
The mean duration of thrombolysis was 24 h. One patient
underwent catheter directed thrombolysis. Out of 35 patients
one patient died due to bleeding post thrombolysis. All pa-
tients who survived were treated with LMWH and oral
anticoagulants.
At 6 months of follow up, out of 34 patients, 7 patients had
recurrent pulmonary thromboembolism in spite of adequate
anticoagulation, 2 patients had persistent pulmonary arterial
hypertension suggestive of chronic pulmonary thromboem-
bolism and surgical pulmonary endarterectomy was done in
these 2 patients. Their follow up at onemonth showed normal
pulmonary artery pressures. 5 patients underwent IVC filter
implantation.
Out of 34 patients, 8 patients who had a provoked PE was
anticoagulated for a period of 6 months and rest of patients
were anticoagulated based on American College of Chest
Physician (ACCP) guidelines.54. Discussion
Pulmonary embolism presents with a wide clinical spectrum,
from asymptomatic disease to life threatening massive PE
that causes hypotension and cardiogenic shock. The clinical
presentation and the investigations including electrocardiog-
raphy, chest radiography, and analysis of arterial blood gases
cannot be relied on to confirm or rule out PE because of lack of
adequate specificity.6
Risk factors for venous thromboembolic disease and pul-
monary embolism arewell characterized in the literature. Risk
factors are present in almost 96% of patients with confirmed
venous thromboembolic disease.7 The major modifiable risk
factors for PE were obesity, cigarette smoking and hyperten-
sion. The most common risk factors in hospitalized patients
were major surgery, cancer, congestive cardiac failure,
chronic obstructive pulmonary disease, chronic kidney dis-
ease especially nephrotic syndrome. The most common
thrombophiliac risk factors for venous thromboembolism are
factor V Leiden mutation, protein C, protein S deficiency,
prothrombin gene mutation, antithrombin III deficiency and
antiphospholipid antibody syndrome.8 In our series only
34.2% of patients had a definite risk factor.
It is believed that diagnosis of pulmonary embolism is
more difficult than treatment. Clinical suspicion of this dis-
ease is of paramount importance in guiding diagnostic testing.
Firstly, the patient’s age is consistently a statistically signifi-
cant univariate predictor for pulmonary embolism. The fre-
quency of pulmonary embolism is increased in elderly
patients.9 On the other hand, the patient’s gender does not
appear to be predictive. Dyspnea, syncope or cyanosis indicate
massive pulmonary embolism.10,11 The lack of typical clinical
manifestations of massive pulmonary embolism might be
related to the insidious onset and progressive development of
thromboembolism.
Fig. 1 e Ventilation perfusion scan showing perfusion defects in lungs (marked with arrows).
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located in the distal pulmonary arterial system, near the
pleural lining. Unexplained dyspnea and chest pain are the
most frequent symptoms, and sudden onset dyspnea and
pleuritic chest pain are the most typical. In our study dyspnea
is the most common symptom followed by syncope and
chest pain.
The ECG in addition to clinical acumen, can be essential in
directing the physician towards the diagnosis. While noFig. 2 e CT Pulmonary Angiogram showing embolus in
right and left main pulmonary arteries.isolated ECG abnormality is definitively associated with PE,
certain constellations of ECG abnormalities have been shown
to be reasonably specific. Several of the more frequently
described associations include: normal ECG, sinus tachy-
cardia, complete and incomplete RBBB, axis changes, transi-
tion zone shift, low voltage complexes, ST segment and
T-wave changes, S1Q3T3 pattern, P-pulmonale and atrial ar-
rhythmias.12,13 Themost common ECG finding in our series in
sinus tachycardia followed by STeT wave changes in anterior
leads, S1Q3T3 pattern and RBBB.
Stein et al12 found that the most common chest X-ray
finding was atelectasis or parenchymal abnormality. It is a
fact, however, that one cannot depend on chest x-ray for the
diagnosis of pulmonary embolism. Although the chest radio-
graph cannot be used to diagnose or exclude PE, it contributes
to the non-invasive diagnostic assessment of PE through the
exclusion of disease processes that may mimic PE.
D-dimer is producedby the breakdownof cross-linkedfibrin
by the fibrinolytic system. D-dimer levels are elevated in acute
thromboembolism and result from the lysis of cross-linked
fibrin within the thrombus. D-dimer levels are, however,
elevated in other conditions and thus are not pathognomonic
for thromboembolic disease. D-dimer testinghas been reported
to have a sensitivity ranging from almost 80e100 percent.14,15
However, such high sensitivity often comes at the cost of low
specificity (high false-positive rates). In the study of Hammond
and Hassan,15 retrospective analysis of a sequential series of
376 patients revealed that no patient with D-dimer of <275 ng/
ml was diagnosed with pulmonary embolism, irrespective of
clinical probability. Egermayer et al16 showed that a negative D-
dimer, a paO2 of80mmHg and a respiratory rate less than 20,
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suspected pulmonary embolism. The results of a D-dimer test,
irrespective of the sensitivity of the assay, cannot be inter-
preted in isolation. In our study D dimerwaspositive in 97.1%of
patients.
Serum troponin levels I and T are sensitive but nonspecific
markers of cardiac myocardial inflammation or injury. They
are elevated in acute coronary artery occlusion and myocar-
dial cellular necrosis from any cause, including scorpion sting
toxins. The stretching of the right ventricle from pressure
overload found with massive or submassive PE may cause the
release of troponins. Right ventricular dysfunction or elevated
troponin levels in an otherwise hemodynamically stable PE
patient predict short-term adverse outcome.17 In our study
troponin values were positive in 68.5 percent of patients.
Since the origin of the thrombus is mostly from deep veins
of the legs, Doppler ultrasound of lower limb veins is a useful
investigation in the diagnosis of PE. Doppler ultrasonography
is positive in 10e20 percent of all patients without leg symp-
toms or signs who undergo evaluation and in approximately
50 percent of patients with proven embolism.18 Therefore, the
possibility of embolism cannot be ruled out on the basis of
negative results on ultrasonography. The sensitivity and
specificity of this examination vary by vein, the best results
are obtained for symptomatic proximal lower limb throm-
bosis showing a 96% sensitivity19 when compared to distal
lower limb thrombosis which has a sensitivity of 73%. Doppler
ultrasound has its value in situations where there is a high
clinical probability of PE and the patient has no past history of
Venous thromboembolism. In our study, 28 patients (80%) had
evidence of DVT in venous Doppler.
The common echocardiographic feature of PE are dilated
pulmonary artery, dilated right atrium, right ventricular
hypokinesis, right ventricular enlargement, reduced left ven-
tricular size, McConnell’s sign, Flattening of the intraventric-
ular septum or paradoxical septal motion, direct visualization
of thrombus in the right heart or pulmonary artery and
distention of the inferior vena cava with loss of normal res-
piratory variation.20 Echocardiography is a useful tool in
identifying high risk patients such as those with right ven-
tricular dysfunction, free floating thrombus and persistent
pulmonary hypertension. All our patients underwent echo-
cardiography. 88.5% had evidence of RV dysfunction and
85.7% had pulmonary arterial hypertension in our study.
Perfusion scan has been used for almost three decades for
the diagnosis of PE and is a valuable tool when the results are
definitive. But approximately 30e70% of scans are non-
diagnostic and the clinician is left in a diagnostic dilemma
of uncertainty.21 Further, it is insensitive in patients with pre-
existing lung diseases, especially the chronic obstructive lung
disease.22 The use of spiral CTPA is a major advancement in
the diagnosis of PE. The sensitivity and specificity for detec-
tion of pulmonary embolus by CTPA at the main, lobar and
segmental levels are greater than 90% with accuracy
decreasing when isolated subsegmental vessels are
involved.21 In our study, perfusion scans were performed in 14
patients and CTPA contributed to diagnosis in 24 patients.
Perfusion scans were of high probability in 11 patients (78.5%)
and non-contributory in the remaining three patients. CTPA
confirmed the diagnosis in these three patients.The ACCP guidelines recommend thrombolytic therapy
be used in pulmonary embolism patients with evidence of
hemodynamic compromise, except in the face of major
contraindications due to bleeding risks (grade 2C). Throm-
bolytic therapy is suggested in selected high risk patients
who do not have hypotension and are at low risk for
bleeding (grade 2C). These high risk patients include pa-
tients with poor perfusion of vital organs, low blood oxygen
level, abnormal serum cardiac enzymes, or abnormal right
heart function on echo. A short infusion time of 2 h for
systemic thrombolytics is suggested, rather than a longer
infusion (grade 2C).5 Tissue plasminogen activator (tPA) has
a short infusion time and has been recommended as the
best agent for this reason. Although most studies demon-
strate the superiority of thrombolytic therapy with respect
to the resolution of radiographic and hemodynamic ab-
normalities within the first 24 h, this advantage disappears
7 days after treatment. Controlled clinical trials have not
demonstrated benefits in terms of reduced mortality rates
or earlier resolution of symptoms when currently
compared with heparin. Until randomized clinical trials
demonstrate a clear morbidity or mortality benefit, the role
of thrombolytic therapy in the management of acute pul-
monary embolism will remain controversial. The currently
accepted indications for thrombolytic therapy include he-
modynamic instability or right ventricular dysfunction
demonstrated on ECHO. Current guidelines for patients
with acute non massive pulmonary embolism recommend
LMWH over UFH (grade 1A). We had thrombolyzed 24
(77.4%) out of the 35 patients with streptokinase with a
mean duration of 24 h. Out of 24 patients thrombolyzed
one patient died due to massive GI bleed and rest of the
patients showed significant clinical improvement and was
discharged.
A patient with a first episode of pulmonary embolism
occurring in the setting of reversible risk factors, should
receive warfarin therapy for 3e6 months. The current ACCP
guidelines recommend that all patients with unprovoked
pulmonary embolism should undergo a risk-to-benefit eval-
uation to determine if long-term therapy is needed (grade
1C). Long term treatment is recommended for these patients
who do not have risk factors for bleeding and in whom ac-
curate anticoagulant monitoring is possible (grade 1A).5 Pa-
tients who have pulmonary embolism and pre existing
irreversible risk factors, such as deficiency of antithrombin
III, protein S and C, factor V Leiden mutation, or the presence
of antiphospholipid antibodies, should be placed on long-
term anticoagulation.5. Conclusion
PE is a clinical problem which is often under recognized and
under diagnosed world over. A high index of suspicion is
necessary to consider the diagnosis. The increasing avail-
ability of newer imaging modalities are likely to improve its
diagnosis When diagnostic techniques are not immediately
available, empiric treatment should be initiated anyway. Early
recognition and aggressive and appropriate therapy improves
the outcome in this potentially fatal condition.
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